AI help for rare tumor case reports
Part of Brain & nervous system clinical trials.
This trial tests whether artificial intelligence can reduce workload when preparing rare tumor case reports. It seeks doctors, medical students, or postdoctoral students to participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a physician, medical student, or postdoctoral student.
- You are involved in preparing rare tumor case reports.
- You are willing to use AI assistance tools.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an artificial intelligence tool can help doctors more accurately diagnose rare diseases. Doctors will use the AI system and answer questions about how well it works.
This study uses artificial intelligence to improve care for adults with rare brain tumors who are scheduled for surgery. It aims to make treatment pathways simpler and better tailored to each patient.
This study uses artificial intelligence to analyze electronic health records (including medical history, lab results, and imaging data) to improve cancer diagnosis and prediction. It aims to help identify cancer earlier and more accurately, potentially leading to better treatment outcomes.
This study tests whether an artificial intelligence system can help doctors figure out what rare disease you have when previous doctors couldn't find an answer. You'll work with the AI tool alongside your regular doctor to try to reach a diagnosis.
This trial tests an AI assistant that helps ICU doctors quickly find patient information and medical records. It may make your work easier and faster.
This study tests an AI system that helps doctors read brain CT and MRI scans. If you had a brain scan for possible tumors, stroke, injury, or other conditions, your data could be used to improve this tool.
Hear when a new Cognitive Symptom trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.